Top 50 Medical VC (Venture Capital) Funds in Denmark in February 2025

Investor	Medical Denmark investments
BioInnovation Institute	12
Novo Holdings	9
Vaekstfonden	6
Vaekstfonden	4
Export and Investment Fund	4
Sunstone Life Science Ventures	4
Seed Capital	3
Forbion Capital Partners	2
VentureFriends	2
People Ventures	2
Industrifonden	2
Crowberry Capital	2
CAPNOVA	2
PSV	2
Wellcome Trust	2
Innovation Fund Denmark	2
p53	1
Novo Ventures	1
LS Polaris Innovation Fund	1
Droia Ventures	1
DigitalDx Ventures	1
GoBeyond	1
Crista Galli Ventures	1
EASME	1
Sofinnova Partners	1
Inkef	1
Eli Lilly	1
Cormorant Asset Management	1
Sagitta Ventures	1
North Ventures	1
Volvere plc	1
SOSV	1
LSP BioVentures	1
SLS Venture	1
Polaris Partners	1
Danske Bank	1
Sound Bioventures	1
CBC Investment Group	1
M Ventures	1
V-Bio Ventures	1
European Investment Bank	1
BlueYard Capital	1
+ND Capital	1
Seventure Partners	1
Nucleus Capital	1
LF Investment	1
Teknoinvest	1
Amino Collective	1
Bioqube Ventures	1
Biofund	1

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
ArcanaBio — ArcanaBio is developing realtime biosurveillance solutions that minimize workplace disruptions and support health & wellness
Zeta Diagnostics — First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Numab — Numab Therapeutics AG
Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, Information Technology, SaaS
Seed, Funding Round, Pre-Seed
Denmark, United States, United Kingdom

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Investment focus

Software, SaaS, Information Technology
Seed, Funding Round, Pre-Seed
Denmark, United States, Norway

Portfolio highlights

Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
Keepit — The Keepit Cloud is the most cost-effective solution on the market with 20+ years of experience. Learn more about our next-level data protection services
kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.

Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Denmark, United States, United Kingdom

Portfolio highlights

Orbex Space — Founded in 2015, Orbex is Europe’s leading private launch services company, focused entirely on supporting the needs of the small satellite industry.Orbex has developed one of the most advanced, low carbon, high performance micro-launch vehicles in the world. They launch customer satellites into polar and sun-synchronous low Earth orbits from aunique, modern launch location in the heart of the European continent.They offer a flexible core launch service and a wide suite of supporting services that make life easier for customers. Their European location means shorter supply lines, easier communications and reduced operational costs. Their advanced launch vehicle means higher reliability, more flexible mission profiles and a regular, scheduled launch service.
Capra Robotics — Our Mobile Robot Platform is a versatile solution optimized for outdoor use in any terrain. Read more about how the CAPRA can work for you.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.

Investment focus

Software, Health Care, SaaS
Seed, Funding Round, Series A
Denmark, United States, United Kingdom

Portfolio highlights

Tembi — Market Intelligence platform with deep market data, insights and predictions for B2B companies that look for a competitive edge.
Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
Embankment Group — Embankment Group is a recruitment consultancy specialising in candidate short markets. We pride ourselves on matching the best talent to the right companies.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Backing ambitious early-stage founders across Europe and MENA

Investment focus

FinTech, E-Commerce, Software
Seed, Series A, Funding Round
Greece, United Kingdom, United States

Portfolio highlights

Barte — VBarte is a benchmark for B2B interactions. They designed it to automate payment procedures in Latin America. They optimize cash flow management for small and midsize enterprises through automated payments and revenue-based financing, enabling users to get easy access to financial metrics and credit payments.
Edgee — Edgee is a full-stack edge platform that aims to alter how workloads and data are processed on the internet. A variety of services are offered by the Edgee platform for edge-based applications.
Simpler — Offer a fast & simple checkout with Simpler. Integrate all major payment options, save on fees & sell more. Get it now!

People Ventures are your dreamcast team of co-founders, investors, executives, engineers, academics and industry experts. Together with talented entrepreneurs — We shape fantastic businesses through operational and commercial execution.

Investment focus

Health Care, Internet of Things, Software
Seed, Pre-Seed, Series A
Denmark, Sweden, United States

Portfolio highlights

Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
proemial — We transform how knowledge-intensive teams make decisions by combining AI with trustworthy sources. Accelerate your team's productivity and stay at the forefront of trends, research, and news, all embedded in where your workflow is happening.
Version Lens — Meet your new Product Management Co-Pilot. Reduce overhead for your product team so you can focus on what truly matters, building outstanding products.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Series A, Seed
Sweden, United States, Denmark

Portfolio highlights

Avassa — Avassa is the one, easy-to-use solution to manage distributed applications across your on-premise, co-located and public cloud compute resources.
Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
ZeroPoint Technologies — ZeroPoint Technologies AB was created in 2016 as a spinout from Chalmers University of Technology. The Intellectual Property Portfolio related to computer memory management was the acquired from the University and transferred into a new startup.The Technology, ideas and many of the people behind and with ZeroPoint comes from Professor PerStenströms research group, which is internationally recognized for excellence within high-performance Computing. Since its creation, ZeroPoint has attracted skilled people from industry, finance and the startup community and raised its’ first round of Venture Capital in 2016.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Investment focus

Software, Gaming, Health Care
Seed, Series A, Pre-Seed
Iceland, Denmark, Finland

Portfolio highlights

Tiimo — Tiimo helps you manage your daily life and improve your wellbeing. Visualize your day. Improve your routines. Stress less.
Quanscient — We are building next generation simulation software-as-a-service utilizing Quantum computing algorithms. Our specialty domain of simulations is Computational Electromagnetics.
Porcelain Fortress — Porcelain Fortress was founded by a small band of romantics in the summer of 2016 in Reykjavik, Iceland.

They are an investment and development company providing capital, solid business experience and a strong network in order to turn innovative ideas into successful businesses. They cover all of Denmark from their offices in Aarhus, Roskilde, Copenhagen, Viborg and Kalundborg.

Investment focus

Software, Information Technology, Internet
Funding Round, Seed, Pre-Seed
Denmark, United States, India

Portfolio highlights

Ulobby — Ulobby is an automated tool for stakeholder management and political monitoring
Mechanic Miner — Mechanic Miner is a 2D construction/survival game with mechanical steam-powered machines. You are stranded on a strange and forbidding planet, where survival is made difficult by hostile animals and plant life. From your home world you did bring a multitool, which is able to craft any kind of machine part - provided the requisite rawmaterials can be found. Relying solely on the technology you brought, you set out to explore a whole world. You can progress through the game by acquiring new types of steam-powered technology elements, that are necessary to delve deeper into the diverse biomes of the planet, and perhaps, ultimately, discover the means to escape. You can construct any kind of machine of your own design - and any kind of machine can be simulated by the game's physics engine - and of course, designs can be shared with your friends.
ResoTher Pharma — ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin 1A as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role.

PreSeed Ventures are the preferred travel companion for trailblazing founders when they set out on the journey of transforming startup dreams to successful businesses. Founded in 2000 they have an exceptional track record of spotting, fostering and financing tomorrow’s winners in syndication with top-tier investors locally and globally. As the namesuggests, PreSeed Ventures operates at the earliest stages, where founders need the professional, operational & systematic support of a VC, but the risks are still too high for most VCs in seed stages. Yet to the powerhouse of experts behind PreSeed Ventures, who have experience from hundreds of startup journey in the pre-seed stage, it is an opportunity to support and nurture the growth of promising startups on the rise, minimizing the time and risk to the next investment round.PreSeed Ventures has grown out of the technological research environment at Denmark’s Technical University, DTU. In 2020 they launch their first full blown commercial venture fund, yet continuing to be a subsidiary company to the university.

Investment focus

Software, Information Technology, SaaS
Seed, Pre-Seed, Funding Round
Denmark, United States, United Kingdom

Portfolio highlights

Cellugy — Biomaterial to Replace Plastic
ZTLment — We empower online platforms and marketplaces to seamlessly hold, manage, and distribute funds in real-time, with full automation and compliance.
Dynelectro — Dynelectro is a green energy technology company that focuses on reducing CO2 emissions by transforming fossil fuels into green fuels.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

RenBio — RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.
Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.

Investment focus

Software, Biotechnology, SaaS
Grant, Pre-Seed, Seed
Denmark, United States

Portfolio highlights

SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
FEESH — FEESH is a groundbreaking biotech company developing sustainable protein alternatives targeted at the aquaculture industry.
Tailwind Biotech — AI-powered synthetic DNA design services for improved strain development. We use Artificial Intelligence to help biotech companies achieve more effective and more efficient bioproduction processes. Our technology designs best-in-class synthetic DNA Promoters and Terminators, and performs gene codon optimizations that help to maximise biomanufacturing yields while reducing development costs.

p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.

Investment focus

Biotechnology, Medical, Life Science
Series A
Norway, Denmark

Portfolio highlights

Calluna Pharma — Join Calluna Pharma to transform therapeutics for inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, we can revolutionize patient care.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

INBRACE — Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases.
Theraxyte — Theraxyte is an innovative nano-drug developer. It focuses on the R&D and application of new nano-drugs, especially innovative drugs.
Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

The LS Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early stage academic research.

Investment focus

Biotechnology, Medical, Biopharma
Series A, Series B, Funding Round
United States, Denmark

Portfolio highlights

Glympse Bio — Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.
Satellite Bio — Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Investment focus

Biotechnology, Medical, Therapeutics
Series A, Series B, Series C
United States, Belgium, The Netherlands

Portfolio highlights

Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
Alesta Therapeutics — Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth

DigitalDx Ventures is a Silicon Valley Venture firm uniquely positioned to find, support, mentor and grow the outliers in digital healthcare. DDX invests in early stage companies who effectively and efficiently harness the power of artificial intelligence and big data to profoundly impact outcomes in both diagnostics and therapeutics.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Funding Round
United States, Canada, Denmark

Portfolio highlights

Nephrosant — NephroSant is a fast-paced diagnostic startup founded by physicians, with a team of world-class scientists, engineers and clinicians, focused on applying the founding team's years of clinical research expertise to improve global kidney health.
GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
Optina Diagnostics — Optina Diagnostics is a leader in the early detection of Alzheimer's disease and develops its solutions using Artificial Intelligence.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Investment focus

Health Care, Wellness, Medical
Seed, Pre-Seed, Series A
United Kingdom, United States, Sweden

Portfolio highlights

Jude — Hey, we're Jude. A healthcare start-up on a mission is to bring bladder care into the mainstream.
Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
Collective Minds Radiology — Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines.

Executive Agency for SMEs

Investment focus

Biotechnology, Health Care, Software
Grant, Seed, Funding Round
Spain, United Kingdom, Switzerland

Portfolio highlights

AGADE — Esoscheletri Agade | Il primo esoscheletro intelligente per lavoratori progettato per ridurre il rischio di disturbi muscolari delle spalle nella movimentazione manuale dei carichi.
BroadBit Batteries — BroadBit is a technology company developing revolutionary new batteries using novel sodium-based chemistries to power the future green economy.
Aenitis Technologies — We develop innovative devices for cells therapy processing using Acoustic Radiation Forces.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Berry Street — Nutrition therapy by registered dietitians covered by insurance.

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
The Netherlands, United States, Germany

Portfolio highlights

Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Revisto — Streamlined MLR review, powered by Al
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
ProQR Therapeutics — ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipelineincludes QRX-704, QRX-504, QRX-421, QRX-323 etc.

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Switzerland

Portfolio highlights

Numab — Numab Therapeutics AG
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Sagitta Ventures invests in early-stage companies in the Nordics and provides long-term capital backing for well-managed businesses that are seeking minority investors without a defined exit horizon.

Investment focus

Aerospace
Series B
Sweden

Portfolio highlights

Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.
Ward 24/7 — WARD 24/7 CSS Wireless Assessment of Respiratory and circulatory Distress (WARD) offers continuous 24/7 observation of high-risk patients with real-time alarms through innovative machine learning algorithms in a Clinical Support System (CSS). Videos on WARD Your browser does not support the video tag. Your browser does not support the video tag. Your browser does not
Heart Aerospace — Heart’s mission is to create the fastest, most affordable and sustainable transportation for regional travel to every corner of the world. Their first aircraft is the ES-19, a nineteen-passenger airliner with an operating range of 400 km. Heart's goal is to have the aircraft certified for commercial operation by 2026.

North Ventures is a venture capital firm that invests in technology-driven startups from seed to Series A.

Investment focus

Financial Services
Series A
Denmark

Portfolio highlights

Monthio — Embrace the future of lending with Open Banking for credit decisioning. Streamline loan applications, increase accessibility, and deliver exceptional customer service.
Cerebriu — Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT.

Volvere is an investment company that invests in or acquires companies which require growth capital. They may be profitable, under-performing or loss-making. We also acquire any company that is complementary to our existing portfolio or which is in a sector in which we have specialist knowledge. Our current trading businesses are organised intothree divisions: security solutions; food manufacturing; and automotive consultancy. Previous areas of investment have included online marketing, safety and risk consulting, transport planning and engineering, and testing and certification.

Investment focus

Medical, Health Care, Biotechnology
Seed
Denmark

Portfolio highlights

MedicQuant — MedicQuant is a medical equipment manufacturing company developing diagnostic kits for blood anticoagulant properties. The company's novel technology, chip, and instrument, Direct Oral Anticoagulants (DOACs), detect blood levels of the anticoagulants, directly from whole blood.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Germany, United Kingdom

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Muna Therapeutics — Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
HotSpot Therapeutics — HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts.

SLS Venture, a Scandinavian-based venture capital company, is the result of the merger of the life science team from The Sixth Swedish National Pension Fund, Medicon Valley Capital and Innoventus. The fund is one of the largest investment funds in Scandinavia in the life science sector with approx. â‚¬ 270 M (USD 325 M) under management.

Investment focus

Health Care, Biotechnology, Medical
Series C, Funding Round, Series A
Denmark, United States, Sweden

Portfolio highlights

AdvanDx — I found a great domain name for sale on Dan.com. Check it out!
OxThera — OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for thetreatment of primary hyperoxaluria.
Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
United States, Ireland, Singapore

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
Auron Therapeutics — A differentiated approach to cure cancer.

Danske Bank is a Nordic universal bank offering a full range of banking services. It was founded 5 October 1871 as Den Danske Landmandsbank, Hypothek- og Vexelbank i Kjøbenhavn (The Danish Farmers' Bank, Mortgage and Exchange Bank of Copenhagen). It is headquartered in Copenhagen, Denmark and is one of the major retail banks in the northernEuropean region with over 5 million retail customers.Danske Bank was number 454 on the Fortune Global 500 list for 2011.

Investment focus

Biotechnology, Apps, Payments
Funding Round, Post-IPO Debt, Debt Financing
Denmark, Sweden, United States

Portfolio highlights

Helen — Helen sell electricity to about 450,000 customers and heat more than 90 percent of Helsinki's properties with district heating.
ITAB Shop Concept — ITAB Shop Concept sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The company offers custom-made fitting concepts, innovative solutions for checkout arena and professional lighting systems.
Renewable Power Capital — Renewable Power Capital invest in the development, construction and long-term ownership of solar, onshore wind and battery storage projects.

Sound Bioventures is a venture capital fund investing in clinical stage companies.

Investment focus

Medical, Biotechnology, Therapeutics
Series A, Seed, Series B
France, Denmark, United States

Portfolio highlights

VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.

CBC Investment Group started in 2009 in the midst of the financial crisis. The banks were on their knees, start-ups of small and medium-sized companies - all of a sudden they saw their credit and credit promises turned into demands for quick repayment and empty words. Serious talented entrepreneurs' ideas and companies risked going completelyunnecessary. In response to this crisis, they started the CBC Investment Group.

Investment focus

Biotechnology, Software, SaaS
Funding Round, Seed, Series B
Sweden, Denmark, Germany

Portfolio highlights

GLX Analytix — GLX Analytix is a biomedical company that develops a new technology to identify a biomarker. The company was founded in 2019 and is based in Copenhagen, Denmark.
Swiftly — World's first AI that applies for jobs. Say goodbye to creating CV's, searching and applying for jobs. Let Swiftly do it for you! Welcome to the new age.
Hugel Control — HUGEL, Inc. strives to be a global company that continuously creates innovative products, promotes universal health, and improves the quality of life through state-of-the-art technology and creativity.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
Belgium, France, United Kingdom

Portfolio highlights

ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases

European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
France, Germany, The Netherlands

Portfolio highlights

BURN — The future of clean cooking
GEWOBA — GEWOBA is a real estate company that manages and provides a diverse portfolio of rental real estate apartments and properties.
Acea — Acea operates in six business segments. The water segment collects, purchases, transports and distributes drinking water, and manages the sewerage system and the purification of wastewaters. The company serves 9 million residents served in Lazio, Tuscany, Umbria, Molise and Campania; The energy segment manages the transmission and distributesroughly 9 TWh of electricity, public lighting; commercial and trading segment activities include energy management, sale of electricity and gas, energy efficiency for domestic customers. The company is targeting growth in electricity generation from renewable (photovoltaic) sources and in electric mobility, with a view to effectively contributing more and more to the energy transition and decarbonisation. The environment segment provides laboratory, research and related consultancy services on the environment and control functions within the water cycle; engineering services and overseas operations providing water services in Latin America.

BlueYard backs founders building the interconnected elements that can become the fabric of our future.

Investment focus

Software, Biotechnology, Internet
Seed, Series A, Funding Round
United States, Germany, United Kingdom

Portfolio highlights

bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
Cryptio — We offer enterprise-grade accounting, reporting, and audit software for your digital assets.
Castelion — We are a modern defense production company building the next generation of military hypersonic, vehicle, and strike systems to deter future wars.

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Switzerland, Denmark

Portfolio highlights

Vandria — At the vanguard of Mitochondrial research
Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Allozymes — Allozymes applies its proprietary platform technology to rapidly develop novel enzymes, revolutionizing the way that industries manufacture complex natural
Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Supporting purpose-driven founders solving systemic challenges to planetary health.

Investment focus

Biotechnology, Information Technology, Food and Beverage
Pre-Seed, Seed, Series A
Germany, United Kingdom, United States

Portfolio highlights

Planet A Foods — The chocolate revolution is here. 100% cocoa-free and unbelievably delicious. We call it QOA. You need to try it!
Ucaneo — We Leveraging the magic of the human body to remove CO2 from the air.
Izote Biosciences — Biomanufacturing Scale-Up Solution

LF Investment is the investment arm of The Lauritzen Foundation, which is the parent company of the shipping companies J. Lauritzen (wholly-owned) and DFDS (42,8% holding). LF Investment has holdings in companies in the oil analysis, measuring equipment, software, biotechnology, and real estate sectors.

Investment focus

Medical, Wellness, Health Care
Funding Round
Denmark

Portfolio highlights

Minervax — We are MinervaX. A clinical stage biotech company focused on making a global impact by developing state-of-the-art vaccines.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VCÂ´s in Scandinaviaaccording to track record of value created for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Series A
Sweden, Norway, United States

Portfolio highlights

GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.

Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.

Investment focus

Health Care, Biotechnology, Medical
Seed, Pre-Seed, Series A
United States, Germany, United Kingdom

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
ExpressionEdits — Redefining the status quo of protein expression
Tandem Health — Focus on providing care, while Tandem helps you easily write medical notes directly after the patient consultation.

A life science venture capital fund - investing globally in exciting science to accelerate breakthrough therapies in patients.

Investment focus

Biotechnology, Therapeutics, Life Science
Seed, Series A, Series B
United States, France, Denmark

Portfolio highlights

CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
Commit Biologics — Add a description for facebook
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.

BIOFUND SpA, established by Fondazione Monte dei Paschi, Bank Monte dei Paschi , Finanziaria Senese di Sviluppo e Fidi Toscana, provides the initial seed capital for companies located in the incubator of Toscana Life Sciences in Siena.

Investment focus

Genetics, Medical, Health Care
Funding Round, Seed
Canada, Denmark, Russian Federation

Portfolio highlights

Exiqon — Exiqon operates in two business areas: Life Sciences and Diagnostics. Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and thedevelopment of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences.
RTM Diagnostika — Diagnostic microwave radio RTM-01-RESThe temperature and rate of growth of malignant tumorsCancer is the terrible disease of breast. That is why the full range of diagnostic measures in mammalogy aimed primarily at identifying it. It is known that the malignant tumor has a higher temperature compared with surrounding tissues. These data werefirst obtained Guture M. French scientist, who, after more than 550 invasive measurements demonstrated that malignancy is determined by its temperature is doubling time. Therefore, the most dangerous, rapidly growing tumors have a very high temperature. It is also known that thermal changes, usually preceded by structural changes. In particular, the thermal changes of the mammary glands come not a moment when the cancer reaches the required size, but much earlier. Studies have shown that even at the stage preceding the malignant growth, namely, when the cells have the expressed proliferation, accompanied by atypical changes, increases the density of microcapillary network, and as a consequence there is a local increase in temperature. Indisputable is the fact that patients with these changes have a high risk of malignancy. Many authors classify this condition as precancerous.The internal temperature - measure of angiogenesisIn 2003, Japanese scientists have shown that the temperature in the cancerous region determined by the density microcapillary network (microvessel density (MVD) [8]. This is the main parameter that characterizes angiogenesis. The density of the microcapillary network when proliferation atypia several times greater than the rate for normal tissues and characterizes the risk of malignancy. in addition, the microcapillary network density refers to the probability of transformation from noninvasive to invasive cancer, the probability of metastasis and tumor growth rate. Therefore, the internal temperature, as a measure of angiogenesis, provides important information about the development of cancer.
Genizon BioSciences — Since 2005, we have helped thousands of people get the perfect domain name.